Optolab Card Diagnose
Diagnosing AIDS, Disease
Diagnosis, Paternity Test
The Ikerlan Centres for Technological Research, connected
to the Mondragon Corporacion Cooperativa (MCC), has
been selected to lead the European Optolab Card project
the aim of which is to design and build up a device
for the quick and effective diagnosis in the treatment
and natural reduction of infectious diseases, evermore
present due to the high mobility of carriers.
The Ikerlan-led project involves a device which is
made up of a portable base and a card that functions
as a laboratory and that automatically controls bacteria-provoked
health risks by means of real-time finding of DNA -
from sample preparation to visual detection.
There are various technology centres from the Basque
Country are participating in the project such as Gaiker
and the Basque Foundation for Innovation and Research
in Healthcare (BIOEF), in addition to other centres
and companies from Germany, Sweden, Denmark ,Austria
and Poland. The project is due to last for 3 years and
it will take an additional three for the new device
to be on the market.
The optic laboratory miniaturised on a card will detect
salmonellosis, the pathogen with the maximum incidence
level right through the European Union (40.7 persons
per 100,000 inhabitants). Moreover, the diagnostic ability
of the new device is very varied, being able to detect
and distinguish chains of DNA. For example, it can able
to detect other infectious diseases such as tuberculosis,flu,
hepatitis, AIDS, etc.
Diagnosis in 15 minutes
Another advantages of the optic card laboratory is
that it is the first system to offer a rapid diagnosis
of an infectious disease within 15 minutes, given that
present analytical methods need a huge number of samples
and protocols that cause the tests to take from 6 hours
to 2 days to be carried out, sufficient time for a whole
community or a important part of the population to turn
out to be infected.
Possible upcoming applications of the laboratory card
are also highly significant, as they can provide doctors
with devices for hereditary diagnosis for the early
detection of molecular diseases, such as degenerative
ones (Parkinson’s, Alzheimer and so on), paternity
tests, genetic disorders, as well as forensic medicine
The survival of the laboratory card is also intended
to significantly improve the quality of the health system,
minimizing hospital admissions, the time exhausted in
hospital and costs relating to diagnoses. The request
of this device will have a great bearing on the minimizing
of infectious diseases.
This is not the initial European project in which Ikerlan
is involved. This MCC-linked Centre for Technological
Research is at present developing new advanced systems
for the diagnosis of cancer, functioning together with
the Basque body Gaiker and BIOEF. This project, relating
a total of 11 countries, will last four years.